Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Feb 16;75:47-55. doi: 10.1016/j.ejca.2017.01.009. [Epub ahead of print]

PMID:
28214657
2.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group..

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2.

PMID:
27939400
3.

Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.

Serie DJ, Joseph RW, Cheville JC, Ho TH, Parasramka M, Hilton T, Thompson RH, Leibovich BC, Parker AS, Eckel-Passow JE.

Eur Urol. 2016 Nov 26. pii: S0302-2838(16)30851-X. doi: 10.1016/j.eururo.2016.11.018. [Epub ahead of print]

PMID:
27899233
4.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81.

5.

A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.

Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, Wong B, Stanton ML, Joseph RW, Castle EP.

Clin Genitourin Cancer. 2016 Sep 8. pii: S1558-7673(16)30260-9. doi: 10.1016/j.clgc.2016.08.026. [Epub ahead of print]

PMID:
27771244
6.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Aug;14(8):945-58.

PMID:
27496110
7.

Patient-derived tumor xenograft models for melanoma drug discovery.

Harris AL, Joseph RW, Copland JA.

Expert Opin Drug Discov. 2016 Sep;11(9):895-906. doi: 10.1080/17460441.2016.1216968.

PMID:
27454070
8.

Efficacy of immunotherapy for metastatic mucosal melanoma.

Shreders A, Joseph RW.

Immunotherapy. 2016 Jul;8(8):843-5. doi: 10.2217/imt-2016-0036. No abstract available.

PMID:
27381682
9.

Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis.

Zhu P, Stanton ML, Castle EP, Joseph RW, Adams DL, Li S, Amstutz P, Tang CM, Ho TH.

J Transl Med. 2016 Jul 2;14(1):198. doi: 10.1186/s12967-016-0953-2.

10.

Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.

Joseph RW, Cappel M, Tzou K, Bagaria S, Gilstrap C, Swaika A, Jambusaria-Pahlajani A.

Melanoma Res. 2016 Aug;26(4):409-12. doi: 10.1097/CMR.0000000000000247.

PMID:
27138458
11.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
12.

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Apr;14(4):450-73.

PMID:
27059193
13.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R.

Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4.

PMID:
26952546
14.

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS.

Mod Pathol. 2016 Jan;29(1):34-42. doi: 10.1038/modpathol.2015.123.

15.

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, Ho TH.

Cancer Immunol Res. 2015 Dec;3(12):1303-7. doi: 10.1158/2326-6066.CIR-15-0150.

16.

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J.

J Urol. 2016 Jan;195(1):180-7. doi: 10.1016/j.juro.2015.07.113.

17.

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.

Ho TH, Nateras RN, Yan H, Park JG, Jensen S, Borges C, Lee JH, Champion MD, Tibes R, Bryce AH, Carballido EM, Todd MA, Joseph RW, Wong WW, Parker AS, Stanton ML, Castle EP.

PLoS One. 2015 Jul 16;10(7):e0132831. doi: 10.1371/journal.pone.0132831.

18.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153.

19.

Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature.

Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW.

Rare Tumors. 2015 Feb 25;7(1):5719. doi: 10.4081/rt.2015.5719.

20.

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

Swaika A, Hammond WA, Joseph RW.

Mol Immunol. 2015 Oct;67(2 Pt A):4-17. doi: 10.1016/j.molimm.2015.02.009. Review.

PMID:
25749122
Items per page

Supplemental Content

Loading ...
Support Center